Skip to main content
PFSA logo

Profusa, Inc. Common Stock (PFSA) Stock Price & Analysis

Profusa, Inc. Common Stock (PFSA) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $0.3455 (-2.51%), as of the Nov 19, 2026 trading session; market cap $1.96M.

Educational signal · not a buy or sell recommendation · How to read this

$0.3455 −$0.0089 (-2.51%) Market Cap $1.96M

Profusa, Inc. Common Stock · PFSA · NASDAQ

Profusa, Inc. is a digital-health company focused on developing tissue-integrating biosensors. Their Lumee™ Oxygen Platform aims to continuously monitor body chemistry and provide AI-powered health insights for chronic conditions.

Price as of Nov 19, 2026

Key Statistics

29 of 100

MoonshotScore v2 · Profusa, Inc. Common Stock (PFSA)

Weak
Business Quality Average (46)
Financial Safety Fragile (7)
Valuation Bubble (8)
Growth Durability Fading (22)
Momentum Falling (11)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fragile balance sheet, stalling growth and an expensive valuation, though quality is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Average; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Falling.

Free cash flow yield is the main valuation drag relative to sector peers.

  • Altman Z -11.64 · Piotroski F 2
  • ROE 148.2% · current ratio 0.03

Holding back: balance-sheet strain, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for PFSA (57 recorded, newest six shown)
RecordedScoreBand
27Weak
27Weak
27Weak
27Weak
29Weak
29Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.3455
Change on the day-2.51%
52-week range$0.3455 – $1537.50
Market capitalisation$1.96M—
Shares traded on the day573.9K

Price & events

Other perspectives

Council score for Profusa, Inc. Common Stock (PFSA): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Negative
Valuation Negative
Growth Durability Weak
Momentum Negative

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Strong
Gross Margin Negative

Read on: Jun 27, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Jun 27, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Profusa, Inc. Common Stock (PFSA), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Profusa, Inc. Common Stock (PFSA) is listed on NASDAQ. It employs 2 people and is led by Jack E. Stover. The market values it at $1.96M.

3 · Financial strengths and risks

What are the financial strengths and risks for Profusa, Inc. Common Stock (PFSA)?

Short answer · as of

What is holding it back is balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -11.64 · Piotroski F 2. Trailing ratios: ROE 148.2% · current ratio 0.03.

Data-derived red flags

  • Listing risk — at $0.3455 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -11.64 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
5 · Peer comparison

How does Profusa, Inc. Common Stock compare with its peers?

Short answer

Profusa, Inc. Common Stock's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Electromed, Inc. (ELMD) Same industry, near in market value$23.40 Nov 18, 2026$191M87 5-pillar Nov 18, 2026
Anika Therapeutics, Inc. (ANIK) Same industry, near in market value$13.28 Nov 19, 2026$178M71 5-pillar Nov 18, 2026
LENSAR, Inc. (LNSR) Same industry, near in market value$4.85 Nov 18, 2026$59.6M44 5-pillar Nov 18, 2026
Acurx Pharmaceuticals, Inc. (ACXP) Named competitor$1.03 Nov 19, 2026$6.24M43 5-pillar Nov 18, 2026
Solana Company (HSDT) Same industry, near in market value$1.66 Nov 19, 2026$104M43 5-pillar Nov 18, 2026
Owlet, Inc. (OWLT) Same industry, near in market value$3.67 Nov 18, 2026$110M41 5-pillar Nov 18, 2026
Hyperion DeFi, Inc. (HYPD) Same industry, near in market value$2.38 Nov 18, 2026$36.2M39 5-pillar Nov 18, 2026
Inogen, Inc. (INGN) Same industry, near in market value$5.42 Nov 19, 2026$141M37 5-pillar Nov 18, 2026
Orthofix Medical Inc. (OFIX) Same industry, near in market value$6.34 Nov 19, 2026$258M36 5-pillar Nov 18, 2026
Apyx Medical Corporation (APYX) Same industry, near in market value$2.49 Nov 18, 2026$105M33 5-pillar Nov 18, 2026
Aprea Therapeutics, Inc. (APRE) Named competitor$0.49 Nov 19, 2026$7.00M32 5-pillar Nov 18, 2026
Aethlon Medical, Inc. (AEMD) Same industry, near in market value$4.84 Nov 19, 2026$7.78M31 5-pillar Nov 18, 2026
Profusa, Inc. Common Stock (PFSA) — this page$0.3455$1.96M29

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Aug 21, 2026

Transactions
20
Identified insiders
3
Purchases
8
Sales
6
Other transactions
6

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held PFSA in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported PFSA in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Profusa, Inc. Common Stock (PFSA)?

Read these with our analysis →

Investor Questions: PFSA Stock

These answers are editorial: 1 of these 9 answers is drawn from the PFSA research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for PFSA?

PFSA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Profusa, Inc. is a digital-health company focused on developing tissue-integrating biosensors.

Is PFSA a good stock to buy?

Stock Expert AI does not rate PFSA buy, sell or hold. Profusa, Inc. Common Stock carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the PFSA stock price today?

The last price recorded for Profusa, Inc. Common Stock (PFSA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

How does Profusa, Inc. Common Stock navigate regulatory approval processes?

As a medical device company, Profusa, Inc. must navigate stringent regulatory approval processes in the United States and other markets.

What are the key factors to evaluate for PFSA?

Profusa, Inc. Common Stock (PFSA) holds a MoonshotScore in the low range. The Lumee™ Oxygen Platform is designed to provide AI-powered health insights for chronic conditions. Not financial advice.

How frequently does PFSA data refresh on this page?

PFSA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven PFSA's recent stock price performance?

Profusa, Inc. Common Stock (PFSA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative tissue-integrating biosensor technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider PFSA overvalued or undervalued right now?

Profusa, Inc. Common Stock (PFSA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of PFSA?

Fractional-share availability for Profusa, Inc. Common Stock (PFSA) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 5 from Financial Modeling Prep (FMP), 6 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.